ATE270712T1 - Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests - Google Patents

Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests

Info

Publication number
ATE270712T1
ATE270712T1 AT96909684T AT96909684T ATE270712T1 AT E270712 T1 ATE270712 T1 AT E270712T1 AT 96909684 T AT96909684 T AT 96909684T AT 96909684 T AT96909684 T AT 96909684T AT E270712 T1 ATE270712 T1 AT E270712T1
Authority
AT
Austria
Prior art keywords
detection
multiple marker
melanoma metastasis
markers
marker test
Prior art date
Application number
AT96909684T
Other languages
English (en)
Inventor
Dave S B Hoon
Fukashi Doi
Andrew J Conrad
Peter Schmid
Original Assignee
Wayne John Cancer Inst
Nat Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne John Cancer Inst, Nat Genetics Inst filed Critical Wayne John Cancer Inst
Application granted granted Critical
Publication of ATE270712T1 publication Critical patent/ATE270712T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Optical Radar Systems And Details Thereof (AREA)
AT96909684T 1995-03-17 1996-03-13 Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests ATE270712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40630795A 1995-03-17 1995-03-17
PCT/US1996/003442 WO1996029430A1 (en) 1995-03-17 1996-03-13 Detection of melanoma or breast metastases with a multiple marker assay

Publications (1)

Publication Number Publication Date
ATE270712T1 true ATE270712T1 (de) 2004-07-15

Family

ID=23607400

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96909684T ATE270712T1 (de) 1995-03-17 1996-03-13 Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests
AT04015872T ATE397097T1 (de) 1995-03-17 1996-03-13 Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04015872T ATE397097T1 (de) 1995-03-17 1996-03-13 Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests

Country Status (6)

Country Link
US (1) US6057105A (de)
EP (2) EP0871768B1 (de)
AT (2) ATE270712T1 (de)
AU (1) AU5310296A (de)
DE (2) DE69632870T2 (de)
WO (1) WO1996029430A1 (de)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
ES2347854T5 (es) 1996-03-26 2014-07-24 Michael S. Kopreski Método que permite el uso de RNA extracelular extraído de plasma o suero para detectar, monitorizar o evaluar un cáncer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
WO1998046788A2 (en) 1997-04-11 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Primers and methods for the detection of disseminated tumor cells
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6824995B1 (en) * 1998-03-03 2004-11-30 Emory University Diagnostic for metastatic prostate cancer
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
DE69926661T2 (de) 1998-09-21 2006-06-08 Xstrata Queensland Ltd. Verfahren zum behandeln von mineralen, die edelmatalle enthalten
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6387697B1 (en) 1998-12-28 2002-05-14 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6958361B2 (en) 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6579973B1 (en) * 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6586177B1 (en) 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
AU1807401A (en) 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
WO2001051664A2 (en) * 2000-01-12 2001-07-19 Dana-Farber Cancer Institute, Inc. Method of detecting and characterizing a neoplasm
US7098008B2 (en) * 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
KR100374423B1 (ko) * 2000-04-25 2003-03-28 주식회사 아이씨엔지 다수의 mage 아형 또는 gage 아형을 인식하는암진단용 프라이머
EP1158001B1 (de) * 2000-05-26 2007-11-14 F. Hoffmann-La Roche Ag Eine Nukleinsäure, die in menschlichen Tumorzellen aufreguliert wird, ein von dieser kodiertes Protein und ein Verfahren zur Tumordiagnose
US20060166227A1 (en) * 2000-06-20 2006-07-27 Stephen Kingsmore Protein expression profiling
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
ATE399216T1 (de) * 2000-07-11 2008-07-15 Kirk Hogan Verfahren und zusammensetzungen zur perioperativen genomischen profilerstellung
US6703204B1 (en) 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
WO2002070751A1 (en) * 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
WO2002088666A2 (en) * 2001-05-01 2002-11-07 Loma Linda University Surgery Medical Group, Inc. Method for identifying lymph nodes
DE60239535D1 (de) 2001-06-18 2011-05-05 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040091857A1 (en) * 2001-07-20 2004-05-13 Nallur Girish N. Gene expression profiling
DK1421215T3 (da) * 2001-07-25 2011-06-27 Oncomedx Inc Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
US7247426B2 (en) 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
JP4336198B2 (ja) * 2001-09-06 2009-09-30 アトナーゲン アクチエンゲゼルシャフト 細胞の選択、および/または定性および/または定量検出のための方法および診断キット
US20030211503A1 (en) * 2001-10-01 2003-11-13 Carpentieri David F. Materials and methods for the diagnosis of pediatric tumors
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US7553619B2 (en) * 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
US7473526B2 (en) * 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
EP1510587B1 (de) * 2002-05-21 2011-07-13 Sysmex Corporation Nukleinsäureamplifikationsprimer zum nachweis von cytokeratinen und untersuchungsverfahren mit verwendung der primer
EP1365034A3 (de) * 2002-05-21 2004-02-18 Bayer HealthCare AG Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Prävention und Behandlung von malignen Tumoren
EP1560924A4 (de) * 2002-08-16 2006-05-31 Wayne John Cancer Inst Molekulare lymphatische kartierung von virchow-lymphknoten
DE10238046A1 (de) 2002-08-20 2004-03-04 Giesing, Michael, Prof. Dr.med. Verfahren zum Untersuchen von Körperflüssigkeiten auf Krebszellen, dessen Verwendung, entsprechende Analysekits und Verwendung bestimmter Wirkstoffe zur Behandlung von Krebs
CA2498783A1 (en) * 2002-09-12 2004-03-25 Yissum Research Development Company Of The Hebrew University Of Jerusale M Method for detection of micro-metastasis
US7910295B2 (en) 2002-11-14 2011-03-22 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimarker quantitative RT-PCR
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
ES2294346T3 (es) * 2002-11-28 2008-04-01 Peter Kufer Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage.
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US6977153B2 (en) 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
US8778606B2 (en) 2003-03-04 2014-07-15 John A. Swetledge At-home cancer test
US7718364B2 (en) * 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
US8043834B2 (en) * 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
EP1757705B1 (de) * 2003-05-01 2009-01-14 Veridex LLC Intraoperativer Lymphknotentest
JP2004350685A (ja) * 2003-05-07 2004-12-16 Tosoh Corp 微小転移の検出法
TWI340168B (en) 2003-05-07 2011-04-11 Tosoh Corp Method of detecting micrometastasis
US20040248103A1 (en) * 2003-06-04 2004-12-09 Feaver William John Proximity-mediated rolling circle amplification
US7824857B2 (en) * 2003-12-02 2010-11-02 Musc Foundation For Research Development Methods and compositions for diagnosing epithelial cell cancer
US20050178726A1 (en) * 2004-02-18 2005-08-18 Robert Belly Disruption of cells and tissues
WO2005084254A2 (en) * 2004-02-27 2005-09-15 Musc Foundation For Research Development Enhanced detection of rna using a panel of truncated gene-specific primers for reverse transcription
EP2290073A3 (de) * 2004-05-28 2011-08-31 Asuragen, Inc. Verfahren und Zusammensetzungen mit MicroRNA
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
EP2272987A3 (de) * 2004-07-09 2012-04-11 University of Pittsburgh of the Commonwealth System of Higher Education Identifizierung von Markern für Speiseröhren-, Dickdarm-, Kopf- und Nackenkrebs und Melanom
JP2008523784A (ja) * 2004-09-14 2008-07-10 ジョン ウェイン キャンサー インスティチュート 体液中癌細胞の検出
FR2875512B1 (fr) * 2004-09-17 2011-02-04 Diagnogene S A Biopuce de diagnostic du caractere metastatique ou localise d'une tumeur mammaire, procede et kit d'utilisation
JP2008515393A (ja) * 2004-09-20 2008-05-15 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 複数モードの多重化反応消去方法
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US8309303B2 (en) 2005-04-01 2012-11-13 Qiagen Gmbh Reverse transcription and amplification of RNA with simultaneous degradation of DNA
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
US8119352B2 (en) * 2006-06-20 2012-02-21 Cepheld Multi-stage amplification reactions by control of sequence replication times
JP2010510964A (ja) * 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド 治療的介入の標的としての、miR−15、miR−26、miR−31、miR−145、miR−147、miR−188、miR−215、miR−216、miR−331、mmu−miR−292−3pによって調節される遺伝子および経路
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
CN101622348A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
CA2671299A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
WO2008073920A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008073919A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
US8197420B2 (en) 2006-12-18 2012-06-12 Magnolia Medical Technologies, Inc. Systems and methods for parenterally procuring bodily-fluid samples with reduced contamination
CA2672951A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compound useful in the treatment of cancer
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CA2689974A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
EP2198050A1 (de) 2007-09-14 2010-06-23 Asuragen, INC. Mikrornas mit unterschiedlicher expression bei zervikalkarzinom und verwendungen davon
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
WO2009154835A2 (en) * 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
US8258111B2 (en) * 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2009155455A1 (en) * 2008-06-19 2009-12-23 John Wayne Cancer Institute Use of runx3 and mir-532-5p as cancer markers and therapeutic targets
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
EP2446271A1 (de) * 2009-06-26 2012-05-02 Erasmus University Medical Center Rotterdam Identifizierung von zirkulierenden tumorzellen (ctcs) mit cd146 bei brustkrebspatienten
AU2011305696A1 (en) * 2010-09-20 2013-05-02 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
SG11201400250UA (en) * 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US8535241B2 (en) 2011-10-13 2013-09-17 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
US8864684B2 (en) 2011-10-13 2014-10-21 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
US9285370B2 (en) 2011-11-04 2016-03-15 Royal College Of Surgeons In Ireland ADAM22 for use as a prognostic variable, and target for therapy, of a metastatic breast cancer disease
US9060724B2 (en) 2012-05-30 2015-06-23 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
US9022951B2 (en) 2012-05-30 2015-05-05 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
WO2014022275A1 (en) 2012-08-01 2014-02-06 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
EP3906952A1 (de) 2012-10-11 2021-11-10 Magnolia Medical Technologies, Inc. Systeme und verfahren zur abgabe einer flüssigkeit an einen patienten mit reduzierter kontamination
RU2537263C2 (ru) * 2012-10-22 2014-12-27 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты)
US9410173B2 (en) * 2012-10-24 2016-08-09 Clontech Laboratories, Inc. Template switch-based methods for producing a product nucleic acid
CA2931983C (en) 2012-11-30 2021-12-07 Magnolia Medical Technologies, Inc. Syringe based fluid diversion mechanism for bodily-fluid sampling
IL303591B2 (en) 2012-12-04 2025-11-01 Magnolia Medical Technologies Inc Sterile bodily-fluid collection device and methods
US10772548B2 (en) 2012-12-04 2020-09-15 Magnolia Medical Technologies, Inc. Sterile bodily-fluid collection device and methods
US20140276578A1 (en) 2013-03-12 2014-09-18 Magnolia Medical Technologies, Inc. Methods and apparatus for selectively occluding the lumen of a needle
EP4218708B1 (de) 2014-03-03 2024-12-18 Magnolia Medical Technologies, Inc. Vorrichtung zur desinfektion eines probenbehälters
EP3769681B1 (de) 2015-06-12 2022-03-02 Magnolia Medical Technologies, Inc. Vorrichtung zur probenahme und fluidtransfer von körperflüssigkeiten
EP3344213B1 (de) 2015-09-03 2020-04-22 Magnolia Medical Technologies, Inc. System zum aufrechterhalten der sterilität eines probenbehälters
CN116250868A (zh) 2017-09-12 2023-06-13 木兰医药技术股份有限公司 流体控制装置及其使用方法
CN110628905A (zh) * 2018-06-25 2019-12-31 武汉菲思特生物科技有限公司 一种用于乳腺原位癌的诊断标志物检测试剂盒及其检测方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458831A1 (de) * 1989-02-16 1991-12-04 BALAZS, Viktor, Dr. Dr. med. Malignitätstest (krebs-test) mit verwendung von der polymerasekettenreaktion
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
DE69333202T2 (de) * 1992-06-26 2004-03-18 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden

Also Published As

Publication number Publication date
EP0871768B1 (de) 2004-07-07
ATE397097T1 (de) 2008-06-15
AU5310296A (en) 1996-10-08
DE69632870D1 (de) 2004-08-12
DE69632870T2 (de) 2005-07-14
EP1505159B1 (de) 2008-05-28
DE69637552D1 (de) 2008-07-10
EP1505159A1 (de) 2005-02-09
EP0871768A1 (de) 1998-10-21
US6057105A (en) 2000-05-02
WO1996029430A1 (en) 1996-09-26

Similar Documents

Publication Publication Date Title
ATE397097T1 (de) Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests
ATE130873T1 (de) Nachweis der expression von neu genen und produkten.
DE50011820D1 (de) Verfahren zur kultivierung von krebszellen aus humangewebe und vorrichtung zur aufbereitung von gewebeproben
EP1035215A3 (de) Verfahren und Sondenset zur Erkennung von Krebs
ATE108490T1 (de) Hybridisierungssonden.
ATE92538T1 (de) Verstaerkung und nachweis von nukleinsaeuresequenzen.
DE60038603D1 (de) Identifikation duktaler öffnungen mittels charakteristischem elektrischen signal
DE69332642D1 (de) Methoden zur detektion von mikrometastasen bei prostata-krebs
DE69225333D1 (de) Verfahren für den Nachweis von Mikroorganismen unter verwendung von direkter undwillkürlicher DNA Amplifikation.
ES2177653T3 (es) Ensayo del cancer que comprende la utilizacion de una sonda derivada del gen h19.
DE60030281D1 (de) Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen
ATE59185T1 (de) Die antigenischen determinanten von hbxag.
ES2047033T3 (es) Un metodo para preparar compuestos de hidroxivitamina d.
DE68926658D1 (de) Diagnostische gene zum nachweis von toxoplasmose
ES2054880T3 (es) Metodo de detectar tumores que contengan un defecto genetico del retinoblastoma.
WO1994012881A3 (en) A method for detecting growing cells using translationally controlled tumor protein p21
ATE309389T1 (de) Verfahren zum entdecken von telomerase-aktivität
ATE15693T1 (de) Zellkultur-verfahren.
DE69528263D1 (de) Verwendung eines spezifischen Markers zur Detektion von Salmonellen mit PCR
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
ATE11930T1 (de) In vitro verfahren zum bestimmen von krebs im saeugergewebe.
BR9708256A (pt) Processo para identificar genes com expresão específica ao síto ou de síto preferido em células de marcacção específicas presentes em um ambiente de células diferente ou não daquele de sua origem e uso do mesmo
NO20032391L (no) Ekspresjonsanalyse av KIAA-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft
DE68925457D1 (de) Diagnoseverfahren für infektionskrankheiten sowie verfahren zum nachweis und identifizierung von mikroorganismen
WO2000061814A8 (en) Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties